Breakthrough: Focal Therapy Offers Safer Prostate Cancer Treatment, Major 10-Year Study Confirms

Breakthrough Study Confirms Focal Therapy Offers Safer, Effective Treatment for Prostate Cancer

A landmark 10-year NHS study led by Imperial College London has delivered compelling evidence that focal therapy—a minimally invasive treatment for prostate cancer—is as effective as traditional surgery or radiotherapy while carrying significantly fewer side effects. The findings mark a potential turning point in how prostate cancer is managed and could reshape treatment protocols across the world.

Published in the European Urology journal, the study followed nearly 3,500 men with intermediate to high-risk prostate cancer who received focal therapy. Ten years after treatment, only two men had died from the disease—outcomes that researchers describe as “excellent” and comparable to conventional approaches like radical prostatectomy or radiation therapy.

What Is Focal Therapy?

Focal therapy is a targeted approach that destroys only the cancerous portion of the prostate while leaving healthy tissue intact. Unlike whole-gland treatments, it uses advanced technologies such as:

• High-intensity focused ultrasound (HIFU) — uses precisely directed ultrasound waves to heat and destroy cancer cells
• Cryotherapy — freezes cancerous tissue using extreme cold delivered through thin probes
• Photodynamic therapy — combines a light-sensitive drug with a laser to target tumors
• Electroporation — uses electrical pulses to disrupt cancer cell membranes

Because the procedure is image-guided and targets only the tumor, patients typically undergo a shorter hospital stay and experience faster recovery times.

Dramatically Fewer Side Effects

One of the most significant findings from the study relates to quality of life. Men treated with focal therapy experienced less than half the risk of debilitating side effects commonly associated with whole-gland treatments. These include:

• Urinary incontinence — rates significantly lower compared to surgery
• Erectile dysfunction — sexual function preserved far more effectively
• Bowel complications — minimal compared to radiotherapy

Rob Huxford, who was diagnosed with prostate cancer at age 44 and received focal therapy in 2020, described his outcomes as “fantastic.” He reports having no long-term issues and expressed frustration that this treatment is not available to men across the entire country.

Why Has Focal Therapy Been Underused?

Despite being introduced more than 20 years ago, focal therapy has remained surprisingly underutilized. Currently, only about 1,000 men per year in the UK receive the treatment, despite estimates suggesting up to 15,000 could benefit. The primary barrier has been a lack of long-term survival data—a gap this study now fills convincingly.

The UK health regulator NICE (National Institute for Health and Care Excellence) has not yet approved focal therapy as a routine treatment because of this previous evidence gap. As a result, routine NHS access is limited to just 10 centers in England, with no provision elsewhere in the UK—a situation campaigners have called a “postcode lottery.”

However, momentum is building. Last month, the UK government committed up to £2.8 million to expand focal therapy provision in England, creating several new treatment centers. Health Innovation and Safety Minister Preet Kaur Gill stated the government’s National Cancer Plan aims to “transform cancer care” and that backing innovations like focal therapy is central to that mission.

Implications for Prostate Cancer Screening

Prostate cancer remains the most common cancer in men in the UK, with more than 64,000 cases diagnosed each year and approximately 12,000 deaths annually. One of the longstanding barriers to introducing a national screening program has been concern that the side effects of treatment could cause more harm than good.

This study changes that calculus. Amy Rylance from Prostate Cancer UK noted that the devastating side effects of traditional treatment have been a major reason screening was not introduced. “Reducing them makes it far more likely we can get to a screening programme for all men sooner,” she said.

A £60 million trial called “Transform” is now underway, investigating the best approach to targeted prostate cancer screening by combining rapid MRI scans with lower-harm treatments such as focal therapy.

Expert Reactions

Joint senior author Professor Hashim Ahmed, consultant urologist at Imperial College London, called the findings a “compelling case for more centres to offer this treatment.” He emphasized that focal therapy “delivers excellent long-term cancer control across a broad range of patients.”

Paul Sayer, founder of charity Prost8 UK and a focal therapy recipient himself, said the study is “incredibly significant” and expressed hope that “this evidence marks the point where every suitable man is routinely offered focal therapy as part of his treatment choices, regardless of where he lives.”

Notable figures who have publicly disclosed their prostate cancer diagnoses include Olympic cycling legend Sir Chris Hoy, former UK Prime Minister Lord David Cameron, and television presenter Jeremy Clarkson—all of whom have helped raise public awareness of the disease and treatment options.

What This Means for Patients

For men diagnosed with localized prostate cancer, this study offers a new and hopeful option. Focal therapy is not suitable for everyone—men whose cancer has spread beyond the prostate or is present in multiple locations within the gland are not ideal candidates. But for those with intermediate or high-risk disease confined to a specific area, the evidence now strongly supports considering focal therapy as a first-line treatment.

Dr. Alastair Lamb from Barts Cancer Institute offered a note of measured optimism, calling focal therapy “an exciting potential treatment” while noting that randomized controlled trials are still needed for definitive conclusions. The PART Trial, the first large randomized controlled trial comparing focal versus radical therapy, is currently underway and its results are eagerly awaited.

Frequently Asked Questions

What is focal therapy for prostate cancer?

Focal therapy is a minimally invasive treatment that targets and destroys only the cancerous part of the prostate gland while sparing healthy tissue. It uses technologies like high-intensity focused ultrasound (HIFU), cryotherapy, or laser therapy.

How effective is focal therapy compared to surgery?

The 10-year NHS study found focal therapy is just as effective as surgery or radiotherapy for localized prostate cancer, with only 2 cancer-related deaths among nearly 3,500 men followed for a decade.

What are the side effects of focal therapy?

Side effects are significantly reduced compared to whole-gland treatments. Patients experience less than half the risk of urinary incontinence and erectile dysfunction associated with surgery or radiation therapy.

Who is eligible for focal therapy?

Focal therapy is suitable for men whose prostate cancer is confined to a single area of the prostate gland and has not spread to other parts of the body. It is not recommended for men with cancer in multiple areas of the prostate or metastatic disease.

Is focal therapy available on the NHS?

Currently, focal therapy is only routinely available at 10 NHS centers in England. The UK government has committed £2.8 million to expand access, and this new study is expected to accelerate wider adoption.

Is focal therapy approved by NICE?

NICE has not yet fully approved focal therapy as a routine treatment option due to previously limited long-term evidence. This new study provides the long-term data regulators were waiting for, and there are growing calls for NICE to review the evidence urgently.

Does focal therapy affect sexual function?

Compared to surgery or radiotherapy, focal therapy has a significantly lower risk of causing erectile dysfunction. Many men retain normal sexual function after treatment.

How long does recovery take after focal therapy?

Recovery is typically faster than with surgery. Most men can return to normal activities within one to two weeks, compared to several weeks or months after radical prostatectomy.